iBio announced promising preclinical data for IBIO-600, a long-acting anti-myostatin antibody, and a first-in-class Activin E antibody, both targeting obesity. Studies in non-human primates suggest IBIO-600 could have a human half-life of up to 130 days, potentially allowing for infrequent dosing. Interim data for the Activin E antibody shows it promotes fat-selective weight loss, which is further enhanced when combined with a GLP-1 receptor agonist like semaglutide.
These developments are noteworthy because they address a critical need in obesity treatment: promoting weight loss while preserving muscle mass. Current treatments often lead to muscle loss, which can negatively impact long-term health and metabolic function. IBIO-600’s potential for a long half-life could significantly improve patient compliance and convenience. The Activin E antibody’s synergistic effect with GLP-1 agonists offers a potential new avenue for combination therapy, addressing the limitations of current monotherapies.
In the IBIO-600 non-human primate study, a single dose led to increased lean mass and decreased fat mass eight weeks post-administration. Allometric scaling suggests a potential human half-life between 57 and 130 days. The Activin E antibody, in a two-week mouse study, induced a 4% weight loss and an 18% reduction in body fat as a monotherapy. Combining it with semaglutide resulted in a 34% weight loss and a 72% reduction in body fat. iBio aims to file a regulatory submission for IBIO-600 in the first quarter of 2026.
These data represent significant progress in developing novel obesity treatments. The potential for long-acting therapies and combination approaches could reshape the obesity treatment landscape, offering patients more effective and convenient options. If these preclinical findings translate to clinical success, iBio’s candidates could become valuable additions to the growing arsenal against obesity.
Jon Napitupulu is Director of Media Relations at The Clinical Trial Vanguard. Jon, a computer data scientist, focuses on the latest clinical trial industry news and trends.
